NICE rejects thyroid cancer drugs

07:21 EDT 23 Aug 2017 | PharmaTimes

It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.

Original Article: NICE rejects thyroid cancer drugs


More From BioPortfolio on "NICE rejects thyroid cancer drugs"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...